New evidence in COPD: is there consensus for clinical practice recommendations?

Industry Theater – American Thoracic Society 2018, May 18–23.

Chaired by Professor David Price (Singapore), with Professors Ken Chapman (Canada) and Dave Singh (UK). Click these links to view their biographies and introduction videos.

During this Novartis supported Industry Theater, a faculty of experts discuss the new evidence informing the role of LABA/LAMA and LABA/LAMA/ICS therapy in COPD management. The importance of personalized COPD management is discussed, including clinical considerations and consensus regarding use of ICS, and evidence-based approaches for ICS withdrawal.

This Novartis sponsored programme is only available to non-US attendees.

Click these links for more information on Onbrez® Breezhaler®, Seebri® Breezhaler® and Ultibro® Breezhaler®.

ATS 2018 - Industry Theater resources